New York, NY (September 01, 2009) – Clinilabs, a contract research organization (CRO) specializing in early phase and specialty clinical drug development, has entered into a strategic alliance with H&J CRO International, a full-service CRO in China. This agreement allows Clinilabs and H&J to exchange knowledge and resources in order to provide clinical drug development services to pharmaceutical and biotechnology companies internationally.
H&J CRO International, Inc. is a global full-service CRO that specialized in regulatory affairs, clinical trial research, clinical data management, SAS programming, biostatistics, and medical writing. The company is headquartered in New Jersey, with two branch offices located in Beijing and Shanghai, P.R. China.
Dr. Gary K. Zammit, President and CEO of Clinilabs stated, “Clinilabs is pleased to enter into this strategic alliance with H&J. This alliance enables Clinilabs to manage early phase and specialty studies in the U.S., while offering our clients the cost efficiencies found in the Asian labor market. We are looking forward to a productive partnership with H&J that will lead both companies to grow their international capabilities."
The two companies plan on combining their business development, project management, and data management efforts internationally. Clinilabs will leverage its Chinese partner H&J to expand its coverage throughout Asia, while H&J will utilize Clinilabs to expand in North America.
“H&J is excited to form this alliance with Clinilabs. We’ve found the basis for a good working partnership that will enable our two companies to expand their presence in the global CRO market,” stated Dr. Fangiang Meng, CEO of H&J.
About Clinilabs Inc.
Clinilabs is a contract research organization (CRO) that provides early phase and specialty clinical drug development services to industry. Our organization offers clients a turn-key solution for single center and multicenter Phase I and II clinical trials. We also offer specialty drug development services in a variety of therapeutic areas. For more information, please visit www.clinilabs.com.
About H&J CRO International, Inc
H&J CRO International, Inc. is a global full-service CRO. The parent company, H&J (Beijing) Medinfor Consultants Ltd., was established in 2003. The company is headquartered in New Jersey U.S., with two branch offices located in Beijing and Shanghai, P.R. China. As of February 2009, H&J CRO had 95 full time employees, with 50% having received Ph.D. or Master’s Degrees in Medicine, Pharmacology, or Biostatistics. The company specializes in regulatory affairs, clinical trial research, clinical data management, SAS programming, biostatistics, and medical writing services. All members of the company’s senior management team have extensive R&D experience in various multinational pharmaceutical companies, with 8 – 24 years in industry. Their sophisticated practical experiences ensure that all projects are conducted efficiently and promptly. H&J’s high standards for quality and efficiency combined with intellectual ability from U.S. and China enable the company to provide cost-effective solutions in data management, SAS programming, biostatistics, and medical writing for phase I, II clinical trials in the U.S., and regulatory affairs services, clinical trial organization, study site monitoring and others CRO services for phase II, III, and IV clinical trials in China.
H&J CRO International, Inc. is a global full-service CRO that specialized in regulatory affairs, clinical trial research, clinical data management, SAS programming, biostatistics, and medical writing. The company is headquartered in New Jersey, with two branch offices located in Beijing and Shanghai, P.R. China.
Dr. Gary K. Zammit, President and CEO of Clinilabs stated, “Clinilabs is pleased to enter into this strategic alliance with H&J. This alliance enables Clinilabs to manage early phase and specialty studies in the U.S., while offering our clients the cost efficiencies found in the Asian labor market. We are looking forward to a productive partnership with H&J that will lead both companies to grow their international capabilities."
The two companies plan on combining their business development, project management, and data management efforts internationally. Clinilabs will leverage its Chinese partner H&J to expand its coverage throughout Asia, while H&J will utilize Clinilabs to expand in North America.
“H&J is excited to form this alliance with Clinilabs. We’ve found the basis for a good working partnership that will enable our two companies to expand their presence in the global CRO market,” stated Dr. Fangiang Meng, CEO of H&J.
About Clinilabs Inc.
Clinilabs is a contract research organization (CRO) that provides early phase and specialty clinical drug development services to industry. Our organization offers clients a turn-key solution for single center and multicenter Phase I and II clinical trials. We also offer specialty drug development services in a variety of therapeutic areas. For more information, please visit www.clinilabs.com.
About H&J CRO International, Inc
H&J CRO International, Inc. is a global full-service CRO. The parent company, H&J (Beijing) Medinfor Consultants Ltd., was established in 2003. The company is headquartered in New Jersey U.S., with two branch offices located in Beijing and Shanghai, P.R. China. As of February 2009, H&J CRO had 95 full time employees, with 50% having received Ph.D. or Master’s Degrees in Medicine, Pharmacology, or Biostatistics. The company specializes in regulatory affairs, clinical trial research, clinical data management, SAS programming, biostatistics, and medical writing services. All members of the company’s senior management team have extensive R&D experience in various multinational pharmaceutical companies, with 8 – 24 years in industry. Their sophisticated practical experiences ensure that all projects are conducted efficiently and promptly. H&J’s high standards for quality and efficiency combined with intellectual ability from U.S. and China enable the company to provide cost-effective solutions in data management, SAS programming, biostatistics, and medical writing for phase I, II clinical trials in the U.S., and regulatory affairs services, clinical trial organization, study site monitoring and others CRO services for phase II, III, and IV clinical trials in China.
